AGC Biologics expanded operations with the purchase of a state-of-the-art commercial biopharmaceutical facility in Boulder, Colorado.
According to International Process Plants, a global buyer and seller of pharmaceutical and biopharmaceutical manufacturing facilities and equipment, the facility formerly owned by AstraZeneca will provide AGC Biologics with additional commercial-scale manufacturing capacity for its biopharmaceutical CDMO business when it enters operation in April 2021, more than 18 months sooner than a new-build facility.
"The addition of this Boulder facility supports AGC Biologics' company-wide expansion initiative, which demonstrates our dedication to support our customers' demand for mammalian projects, now and into the future," says AGC Biologics CEO Patricio Massera. "This facility will enable us to continue to advance the development, manufacturing and commercial functions within our dynamic global company."
"IPP acted as the buyer's exclusive agent for AGC Biologics in their purchase from AstraZeneca," said Ron Gale, President of IPP. "We are glad to be working with AGC Biologics and wish them success for future operations at the site. At the core of our business, we create win-win scenarios for companies looking to exit an asset, companies looking to expand, and communities looking to continue and grow their workforce. We are confident that this outcome is a win for AGC Biologics as the buyer, Boulder and the region's skilled biopharma workforce, and a win for AstraZeneca as the seller."
"Especially in light of the COVID-19 response, we have several large and small molecule production facilities and systems for end users to consider as they look to expand, “he said. “IPP looks forward to participating in future transactions to both help companies move rapidly to increase capacity as well as help companies divest from unneeded assets in these challenging times."